Sciwind Biosciences Co. Ltd., a clinical-stage biopharmaceutical company, announced on Thursday, December 9, that it completed enrolment of patients in its phase two clinical trial of XW003 for type 2 diabetes in China.

The product is a novel, long-lasting glucagon-like peptide-1 (GLP-1) peptide analogue optimised for improved biological activity, cost-effective manufacturing, and once weekly dosing. The company says that it is indicated to be safe and well tolerated, and induced dose-dependent weight decrease in healthy volunteers in a Phase 1 clinical trial that was completed during early 2021 in Australia.

The Phase 2 study is being carried out in China in around 144 subjects with type 2 diabetes. Subjects are divided into three study cohorts and treated with varying doses of XW003 for 20 weeks with a five-week follow-up period. The aim of the study is to assess the safety, tolerability and treatment effects of the product in diabetic patients. XW003 is also being assessed in an international, multi-centre, phase two study in non-diabetic patients with obesity.